Chris Brinsmead Appointed Chairman of Proteus Biomedical Europe
2012 UK Launch of First Commercial Product Planned
(Business Wire) — Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that Chris Brinsmead has joined the company as Chairman, Proteus Biomedical Europe. Brinsmead has over 30 years of experience in the global pharmaceutical industry and more recently advising the United Kingdom government on health and life sciences policy. He will be instrumental in guiding the commercial launch of Proteus’s first product, Helius™, and the development of Proteus’s organization in Europe.
Helius is a consumer and family caregiver product that provides assurance and peace of mind to individuals struggling with complex medication regimens and health issues. Combining sensor-enabled tablets, a wearable physiologic monitor, and an advanced mobile health (mHealth) user experience and information service, Helius allows these consumers to remain independent in their own homes and their loved ones to help take care of them. Launched first in the UK in 2012, Helius will be marketed and sold by retail pharmacies, supported by counseling from community pharmacists, and paid for by consumers and their families. The product will also be used by home care services, care homes and other institutions to improve the quality and efficiency of care and reduce costs.
The Helius product offering is based on Proteus’s Raisin™ System, a sensor-enabled technology platform that collects and aggregates various behavioral, physiologic and therapeutic metrics—such as medication adherence, heart rate, sleep patterns, physical activity and stress levels—into meaningful and appropriate personal health management tools delivered to the mobile devices consumers already carry in their purses and pockets. The Raisin System is CE Mark approved for distribution and commercialization in the European Union.
Mr. Brinsmead currently serves as the Life Sciences Business Advisor to the UK government of Prime Minister David Cameron and was previously appointed by then Prime Minister Gordon Brown as a business ambassador with a remit to promote UK life science excellence abroad. He has extensive UK and international management and marketing experience in the pharmaceutical industry, having previously served as Chairman of Astra Zeneca UK Limited, as President of Astra Zeneca UK Limited, and in other senior global marketing and management roles with AstraZeneca, Zeneca and ICI Pharmaceuticals. He also served as the President of the Association of British Pharmaceutical Industry (ABPI). He holds a BSc in Civil Engineering from Nottingham University and Masters in Business Science from Manchester Business School.
“I believe that Proteus is developing a potential game changer for the way in which consumers take their medicines, understand their chronic conditions and manage their health and wellness,” commented Mr. Brinsmead. “With the launch of Helius, first in the UK and then across Europe, we will be building the foundation for a new kind of twenty-first century medical business—one that is as shaped, personalized and embraced by consumers as are the mobile phones, social media sites and other digital products that increasingly populate and define our daily lives.”
“We are delighted that someone with as distinguished a career as Chris Brinsmead has assumed such an important leadership role in commercializing our first products,” said Andrew Thompson, Chief Executive Officer at Proteus.
About Proteus Biomedical, Inc.
Proteus Biomedical is pioneering intelligent medicine, an emerging field of advanced therapeutics that integrates in-body computer, sensor and mobile communications technologies into existing pharmaceutical, medical device and consumer products. Proteus’ proprietary computing and sensing technologies enable proven therapies to be personalized, offering broad potential benefits across a range of care settings and therapeutic areas. Proteus is developing and commercializing intelligent medicine products in partnership with global leaders from multiple industries, including Novartis, Medtronic, Avery Dennison, ON Semiconductor and Kaiser Permanente. More information about Proteus Biomedical can be found at www.proteusbiomed.com.